Literature DB >> 21206484

Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.

Martin J Hicks1, Bishnu P De, Jonathan B Rosenberg, Jesse T Davidson, Amira Y Moreno, Kim D Janda, Sunmee Wee, George F Koob, Neil R Hackett, Stephen M Kaminsky, Stefan Worgall, Miklos Toth, Jason G Mezey, Ronald G Crystal.   

Abstract

Based on the concept that anticocaine antibodies could prevent inhaled cocaine from reaching its target receptors in the brain, an effective anticocaine vaccine could help reverse cocaine addiction. Leveraging the knowledge that E1(-)E3(-) adenovirus (Ad) gene transfer vectors are potent immunogens, we have developed a novel vaccine platform for addictive drugs by covalently linking a cocaine analog to the capsid proteins of noninfectious, disrupted Ad vector. The Ad-based anticocaine vaccine evokes high-titer anticocaine antibodies in mice sufficient to completely reverse, on a persistent basis, the hyperlocomotor activity induced by intravenous administration of cocaine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21206484      PMCID: PMC3048190          DOI: 10.1038/mt.2010.280

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  33 in total

Review 1.  Control of influenza and poliomyelitis with killed virus vaccines.

Authors:  J Salk; D Salk
Journal:  Science       Date:  1977-03-04       Impact factor: 47.728

2.  Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay.

Authors:  R Müller
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

3.  Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response.

Authors:  Valérie Molinier-Frenkel; Renée Lengagne; Florence Gaden; Saw-See Hong; Jeannine Choppin; Hanne Gahery-Ségard; Pierre Boulanger; Jean-Gérard Guillet
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model.

Authors:  K M Kantak; S L Collins; E G Lipman; J Bond; K Giovanoni; B S Fox
Journal:  Psychopharmacology (Berl)       Date:  2000-02       Impact factor: 4.530

5.  Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.

Authors:  Ben-Gary Harvey; Jaman Maroni; Kelley A O'Donoghue; Karen W Chu; Jolene C Muscat; Allison L Pippo; Connie E Wright; Charleen Hollmann; Juan P Wisnivesky; Paul D Kessler; Henrik S Rasmussen; Todd K Rosengart; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2002-01-01       Impact factor: 5.695

6.  Suppression of psychoactive effects of cocaine by active immunization.

Authors:  M R Carrera; J A Ashley; L H Parsons; P Wirsching; G F Koob; K D Janda
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

7.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Authors:  M A Rosenfeld; K Yoshimura; B C Trapnell; K Yoneyama; E R Rosenthal; W Dalemans; M Fukayama; J Bargon; L E Stier; L Stratford-Perricaudet
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

8.  Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice.

Authors:  M Benuck; A Lajtha; M E Reith
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

9.  A critical evaluation of a nicotine vaccine within a self-administration behavioral model.

Authors:  Amira Y Moreno; Marc R Azar; Noelle A Warren; Tobin J Dickerson; George F Koob; Kim D Janda
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

10.  A second-generation vaccine protects against the psychoactive effects of cocaine.

Authors:  M R Carrera; J A Ashley; P Wirsching; G F Koob; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  35 in total

Review 1.  Vaccines targeting drugs of abuse: is the glass half-empty or half-full?

Authors:  Kim D Janda; Jennifer B Treweek
Journal:  Nat Rev Immunol       Date:  2011-12-16       Impact factor: 53.106

Review 2.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 3.  Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity.

Authors:  Charles W Schindler; Steven R Goldberg
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 4.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

5.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

Review 6.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

7.  A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats.

Authors:  Michelle L Miller; Amira Y Moreno; Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Brittani D Vaillancourt; M Jerry Wright; Kim D Janda; Michael A Taffe
Journal:  Biol Psychiatry       Date:  2012-10-23       Impact factor: 13.382

8.  Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.

Authors:  Suzette M Evans; Richard W Foltin; Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Kim D Janda; Stephen M Kaminsky; Ronald G Crystal
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

Review 9.  Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Authors:  Stephen Brimijoin; Xiaoyun Shen; Frank Orson; Thomas Kosten
Journal:  Expert Rev Vaccines       Date:  2013-03       Impact factor: 5.217

10.  Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.

Authors:  Jonathan B Rosenberg; Bishnu P De; Martin J Hicks; Kim D Janda; Stephen M Kaminsky; Stefan Worgall; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2013-06       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.